Mr Engle has broad management and financial background including six years at Dey LP, where he was the firm’s president and CEO.
Mr Engle’s background also includes senior executive positions with Merck Generics Group, a division of Merck KGaA, and Allergan.
Chris Stern, chairman and CEO of Oxygen Biotherapeutics, said: “I’m very pleased that Mel has agreed to join our board. He has the business acumen and experience in the pharmaceutical industry to help us develop and grow as we work to bring Oxycyte-based products to the market.”